On November 11, cell-engineering company MaxCyte announced a definitive agreement to acquire Akron BioProducts from affiliates of Arcline Investment Management for total consideration of $151.8 million. The transaction is expected to close before the end of 2026, subject to customary closing conditions.
Headquartered in Boca Raton, Florida, Akron supplies GMP-grade reagents and ancillary materials used throughout the cell therapy manufacturing workflow, including electroporation, expansion and cryopreservation. Its products are embedded in customers' validated manufacturing processes and regulatory submissions, supported by drug master files (DMFs) referenced in INDs and BLAs.
The combination is expected to nearly double MaxCyte's revenue base and, through Akron's products, expand MaxCyte into the viral ex-vivo cell therapy market. The combined business will be embedded in the workflow of five approved therapies and support more than 100 clinical programs.
Under the terms, MaxCyte will pay $105.0 million in cash at closing, subject to customary adjustments, plus 20,639,733 shares valued at approximately $26.8 million based on the November 9 closing price, and $20.0 million in total guaranteed deferred payments. Akron is expected to generate approximately $28 million in revenue in 2026.

Source: https://theregenreport.com/2026/11/11/maxcyte-to-acquire-cell-therapy-reagent-supplier-akron-bio-for-151-8-million/